<DOC>
	<DOCNO>NCT01760564</DOCNO>
	<brief_summary>To evaluate change cognitive function miglustat treatment Niemann-Pick type C patient .</brief_summary>
	<brief_title>Application Miglustat Patients With Niemann-Pick Type C</brief_title>
	<detailed_description>Patients Niemann-Pick C disease treat Miglutat 200mg tid . Neurologic evaluation safety monitor periodically .</detailed_description>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Confirm diagnosis NiemannPick C disease Symptomatic include motor mental symptom Unknown severe diarrhea 7 day Allergy miglustat</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Niemann-Pick disease type C</keyword>
	<keyword>miglustat</keyword>
</DOC>